Browse Correspondence
- CorrespondenceVOL. 387 No. 9, Sep 01, 2022
Long-Term MC4R Agonist Treatment in POMC-Deficient Patients
N Engl J Med 2022; 387:852-854In this follow-up study involving two patients with POMC deficiency, treatment with the MC4R agonist setmelanotide resulted in a long-term reduction in body weight and BMI and induced satiety.
- CorrespondenceVOL. 387 No. 9, Sep 01, 2022
Pretomanid in the Treatment of Patients with Tuberculosis in the United States
N Engl J Med 2022; 387:850-852Investigators report findings from the use of an all-oral regimen of bedaquiline, pretomanid, and linezolid in patients in the United States with multidrug-resistant or extensively drug-resistant tuberculosis.
- CorrespondenceVOL. 387 No. 9, Sep 01, 2022
Tranexamic Acid in Patients Undergoing Noncardiac Surgery
N Engl J Med 2022; 387:858-859To the Editor: The perioperative use of antiplatelet and anticoagulant agents may vary among physicians.1,2 Indeed, in the Perioperative Ischemic Evaluation–3 (POISE-3) trial conducted by Devereaux et al. (May 26 issue),3 the use of such agents was left to the discretion of the attending physician....
- CorrespondenceVOL. 387 No. 9, Sep 01, 2022
Sequential Stem Cell–Kidney Transplantation in Schimke Immuno-osseous Dysplasia
N Engl J Med 2022; 387:859-860To the Editor: Nearly half the patients with Schimke immuno-osseous dysplasia (SIOD) may have vascular or neurologic problems, including headaches, transient ischemic attacks (TIAs), and cerebral ischemic events. These problems contribute to the morbidity and mortality associated with this condition.1,2 Unfortunately, the underlying pathophysiology of vascular disease...
- CorrespondenceVOL. 387 No. 9, Sep 01, 2022
PD-1 Blockade in Mismatch Repair–Deficient Rectal Cancer
N Engl J Med 2022; 387:854-856To the Editor: Mismatch-repair status and extended analyses of RAS mutations in patients with colorectal cancer can be predictive and prognostic.1,2 Cercek et al. (June 23 issue)3 report a complete clinical response in 12 patients with locally advanced, mismatch repair–deficient rectal cancer after...
- CorrespondenceVOL. 387 No. 9, Sep 01, 2022
Restriction of Intravenous Fluid in ICU Patients with Septic Shock
N Engl J Med 2022; 387:856-857To the Editor: In the Conservative versus Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care (CLASSIC) trial, Meyhoff et al. (June 30 issue)1 found similar numbers of death at 90 days in patients with septic shock who received resuscitation with a restrictive-fluid strategy (42.3%)...
- CorrespondenceAug 31, 2022
Risk of BA.5 Infection among Persons Exposed to Previous SARS-CoV-2 Variants
10.1056/NEJMc2209479Conventional wisdom is that previous infection with omicron subvariant BA.1 or BA.2 does not protect against BA.5, but data from Portugal show considerable protection against BA.5 infection from previous BA.1 or BA.2 infection.
- CorrespondenceVOL. 387 No. 8, Aug 25, 2022
Trial of a Phosphodiesterase 4 Inhibitor for Idiopathic Pulmonary Fibrosis
N Engl J Med 2022; 387:761-762To the Editor: Richeldi et al. (June 9 issue)1 reported prompt stabilization in lung function in patients with idiopathic pulmonary fibrosis (IPF) who received a preferential phosphodiesterase 4B (PDE4B) inhibitor and a rapid decline in the forced vital capacity (FVC) in patients who received placebo. Over a...
- CorrespondenceVOL. 387 No. 8, Aug 25, 2022
Case 16-2022: A Man with Fevers, Night Sweats, and a Mediastinal Mass
N Engl J Med 2022; 387:762-764To the Editor: The report by Fajgenbaum et al. (May 26 issue)1 describes a patient with idiopathic multicentric Castleman’s disease (iMCD) with the TAFRO (thrombocytopenia, anasarca, fever or an elevated C-reactive protein level or both, renal insufficiency or reticulin fibrosis or both, and organomegaly) clinical subtype that...
- CorrespondenceVOL. 387 No. 8, Aug 25, 2022
Circulating Tumor DNA Guiding Adjuvant Therapy in Colon Cancer
N Engl J Med 2022; 387:759-760To the Editor: Tie and colleagues (June 16 issue)1 reported that basing decisions regarding adjuvant chemotherapy in stage II colon cancer on the presence of circulating tumor DNA (ctDNA) after surgery was noninferior to basing such decisions on standard clinicopathological features and that it reduced chemotherapy use...
- CorrespondenceVOL. 387 No. 8, Aug 25, 2022
Edible Cannabis Legalization and Unintentional Poisonings in Children
N Engl J Med 2022; 387:757-759Canadian data show that legalization of cannabis for adults has been associated with increased hospitalizations for unintentional cannabis poisoning in children, mostly after legalization of cannabis edibles.
- CorrespondenceVOL. 387 No. 7, Aug 18, 2022
Treatment for Mild Chronic Hypertension during Pregnancy
N Engl J Med 2022; 387:663-664To the Editor: In their article on the Chronic Hypertension and Pregnancy (CHAP) trial, Tita et al. (May 12 issue)1 report better pregnancy outcomes in women assigned to active treatment of mild chronic hypertension (blood-pressure goal, <140/90 mm Hg) than in those assigned to treatment only for severe hypertension, with...
- CorrespondenceVOL. 387 No. 7, Aug 18, 2022
Japanese Encephalitis in Australia — A Sentinel Case
N Engl J Med 2022; 387:661-662A patient in whom Japanese encephalitis was diagnosed in February 2021 has been identified as a likely sentinel human case of the 2022 outbreak of the disease in Australia.
- CorrespondenceVOL. 387 No. 7, Aug 18, 2022
Albuterol–Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma
N Engl J Med 2022; 387:662-663To the Editor: In the MANDALA trial, Papi et al. (June 2 issue)1 showed the superiority of high-dose budesonide–albuterol to albuterol as reliever therapy for reducing exacerbations in patients with uncontrolled moderate-to-severe asthma. Only 27% of the patients were receiving high-dose inhaled glucocorticoid–long-acting β2 -agonist (LABA)...
- CorrespondenceVOL. 387 No. 7, Aug 18, 2022
Prevention of Anal Cancer
N Engl J Med 2022; 387:665-667To the Editor: The findings reported by Palefsky et al. (June 16 issue)1 in the Anal Cancer–HSIL [high-grade squamous intraepithelial lesion] Outcomes Research (ANCHOR) trial provide proof of principle that high-resolution anoscopy–guided periodic ablation of HSIL reduces the risk of anal cancer among human immunodeficiency virus (HIV)–positive...
- CorrespondenceVOL. 387 No. 7, Aug 18, 2022
Frostbite — Diagnosis and Therapy
N Engl J Med 2022; 387:667-668To the Editor: Sheridan et al. (June. 9 issue)1 review the diagnosis and treatment of frostbite. The authors note that the first step in the management of frostbite is evaluation for trauma and hypothermia. Since hypothermia and frostbite frequently are concomitant, sudden cardiac arrest may occur when...
- CorrespondenceVOL. 387 No. 7, Aug 18, 2022
Rapid Nanopore Sequencing–Based Screen for Aneuploidy in Reproductive Care
N Engl J Med 2022; 387:658-660A study of DNA sequencing of reproductive tissues (e.g., products of conception after miscarriage) to test for aneuploidy supports the use of this approach to guide prenatal and fertility care.
- CorrespondenceVOL. 387 No. 6, Aug 11, 2022
Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
N Engl J Med 2022; 387:571-573To the Editor: In the CheckMate 816 trial, Forde and colleagues (May 26 issue)1 concluded that neoadjuvant treatment with nivolumab did not impede the feasibility of surgery, which is the curative treatment for lung cancer. However, in the experimental group (in which patients received nivolumab plus platinum-based...
- CorrespondenceVOL. 387 No. 6, Aug 11, 2022
Use of eGFR in Older Adults with Kidney Disease
N Engl J Med 2022; 387:574-575To the Editor: In their review article, Levey et al. (June 2 issue)1 stress creatinine-based estimates of the glomerular filtration rate (eGFRcr) as first-line tools to evaluate kidney function in real-world practice. However, they scarcely addressed the effect of age-related changes in body composition on the eGFR,...
- CorrespondenceVOL. 387 No. 6, Aug 11, 2022
HIV Prevention and the 340B Drug Pricing Program
N Engl J Med 2022; 387:575-576To the Editor: In their Perspective article, Marcus et al. (June 2 issue)1 warn that provision of human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) by entities participating in the 340B Drug Pricing Program, when such provision relies on revenue from the prescription of brand-name drugs, may lead...